Comerica Securities’s Haemonetics HAE Stock Holding History

Comerica Securities’s Portfolio HAE Stock Details HAE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-12	Closed	-$944	–	860
2022 Q4	$944	Buy	+12	New	+$965	﹤0.01%	1362

Other funds holding HAE

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Schroder Investment Management Group London, United Kingdom $122B AUM 29.27% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Comerica Securities's HAE Position: Q1 2023 in Review

Comerica Securities sold out of Haemonetics (HAE) in Q1 2023, closing a stake of 12 shares — an estimated $944 sold.

Comerica Securities first reported a position in HAE in Q4 2022 and held it in 1 quarter. The position peaked at $944 in Q4 2022. 301 funds tracked by Wall St. Rank hold HAE as of Q1 2023.

Comerica Securities reported no remaining Haemonetics position as of Q1 2023 after selling out during the quarter.
Comerica Securities sold 12 Haemonetics shares in Q1 2023, an estimated $944.
Comerica Securities first reported a position in Haemonetics in Q4 2022 and held it in 1 quarter.
Comerica Securities's Haemonetics position peaked at $944 in Q4 2022.
301 funds tracked by Wall St. Rank held Haemonetics as of Q1 2023.

Based on Comerica Securities's 13F filing for Q1 2023, filed 27 Apr 2023.